San Francisco startup Structure Therapeutics is also working on an oral, at the time-every day GLP-1 drug known as GSBR-1290—the drug surpassed Wall Street’s expectations in June each time a mid-stage review showed normal weight loss of all-around 6% and it plans to start A further m